Parabilis (PBLS) director reports vested stock option positions

Rhea-AI Filing Summary

Parabilis Medicines, Inc. director Richard Klausner reported his existing stock option holdings in this initial Form 3. He holds options over 48,736 shares of Common Stock with an exercise price of $1.88 per share that are fully vested and expire on December 10, 2034.

He also holds options over 21,273 shares of Common Stock with an exercise price of $4.62 per share, expiring on June 27, 2028. For this second grant, 25% vested on December 11, 2025, with the remaining shares vesting in thirty-six equal monthly installments, subject to his continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Klausner Richard

Role null

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 21,273 shares (Direct, null)

Footnotes (1)

1. The shares subject to this option are fully vested. 25% of the shares subject to this option vested and became exercisable on December 11, 2025 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Option exercise price: $1.88 per share Underlying shares (first grant): 48,736 shares Option exercise price (second grant): $4.62 per share +1 more

4 metrics

Option exercise price $1.88 per share Stock option over 48,736 underlying common shares, expiring December 10, 2034

Underlying shares (first grant) 48,736 shares Common Stock underlying fully vested option at $1.88 exercise price

Option exercise price (second grant) $4.62 per share Stock option over 21,273 underlying common shares, expiring June 27, 2028

Underlying shares (second grant) 21,273 shares Common Stock underlying option vesting 25% on December 11, 2025, then monthly

Key Terms

Stock Option (right to buy), exercise price, underlying security, vested, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 1.8800 and 4.6200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying_security_title: Common Stock"

vested financial

"The shares subject to this option are fully vested."

vesting installments financial

"remainder vesting in thirty-six (36) equal monthly installments thereafter"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 06/12/2026 - 01:32 PM Accepted by SEC EDGAR 06/09/2026 - 09:12 PM Learn about SEC filing dates

FAQ

What does the Parabilis Medicines (PBLS) Form 3 filing by Richard Klausner show?

The Form 3 shows director Richard Klausner’s existing stock option holdings in Parabilis Medicines. It reports two option grants over 48,736 and 21,273 underlying common shares with specified exercise prices, vesting schedules, and expiration dates, without indicating any recent buy or sell transactions.

How many Parabilis Medicines (PBLS) shares are covered by Klausner’s reported options?

Klausner’s options cover 48,736 underlying common shares at a $1.88 exercise price and 21,273 underlying common shares at a $4.62 exercise price. These figures reflect the number of Parabilis Medicines shares issuable upon exercise of his reported stock options, subject to vesting and expiry.

What are the exercise prices and expirations of Klausner’s Parabilis (PBLS) stock options?

One option has an exercise price of $1.88 per share and expires on December 10, 2034. The other has an exercise price of $4.62 per share and expires on June 27, 2028. These terms define the cost and time window for exercising each option.

What is the vesting schedule for Klausner’s higher-priced Parabilis (PBLS) option grant?

For the $4.62 option, 25% of the shares vested and became exercisable on December 11, 2025. The remaining shares vest in 36 equal monthly installments, conditioned on Klausner’s continued service with Parabilis Medicines on each vesting date, according to the footnote.

Did Richard Klausner buy or sell Parabilis (PBLS) shares in this Form 3?

The Form 3 does not report any share purchases or sales. It lists Klausner’s existing stock option positions as of the reporting date. Both entries are classified as holdings, with no transaction code indicating open-market buys, sells, exercises, gifts, or other dispositions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Klausner Richard

(Last) (First) (Middle)

C/O PARABILIS MEDICINES, INC.

30 ACORN PARK DRIVE, 6TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/09/2026

3. Issuer Name and Ticker or Trading Symbol
Parabilis Medicines, Inc. [ PBLS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	06/27/2028	Common Stock	21,273	$4.62	D
Stock Option (right to buy)	(2)	12/10/2034	Common Stock	48,736	$1.88	D

Explanation of Responses:

1. The shares subject to this option are fully vested.

2. 25% of the shares subject to this option vested and became exercisable on December 11, 2025 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Teresa Jurgensen, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)